Scientific name: 2-(2-chlorophenyl)-2-(methylamino)cyclohexanone

Common names: Ketamine, ketamine hydrochloride, K, Special K, Ket. Research designations include CI-581 (the original Parke-Davis code), Ketalar, and Ketaject. The isolated S(+) enantiomer is marketed as esketamine (brand name Spravato).

Chemical class: Arylcyclohexylamine. Ketamine belongs to the same structural family as phencyclidine (PCP), sharing a cyclohexane ring fused to an aromatic ring, but with a substantially milder pharmacological profile.

Molecular formula: C₁₃H₁₆ClNO (molecular weight: 237.72 g/mol)

Substance type: Fully synthetic. Ketamine does not occur in any known plant, fungus, or organism. It exists as a white to off-white crystalline powder, highly soluble in water, with a characteristic bitter, numbing taste reflecting its local anesthetic properties.

Taxonomic position: Ketamine is a dissociative, not a classical psychedelic. It does not belong to the tryptamine or phenethylamine families and does not act through serotonin pathways. Its primary mechanism, NMDA receptor antagonism, places it in a distinct pharmacological category alongside PCP, dextromethorphan (DXM), and memantine.

Ketamine reaches people through several distinct pathways, each shaping the experience differently.

Clinical settings represent the most structured encounter. Ketamine infusion clinics administer pharmaceutical-grade ketamine intravenously for treatment-resistant depression and chronic pain. The FDA-approved intranasal formulation of esketamine (Spravato) is available in certified clinics for treatment-resistant depression and acute suicidal ideation. Research programs at institutions including the National Institute of Mental Health, Johns Hopkins, and Yale continue to explore applications across depression, PTSD, and anxiety.

Route matters. The way ketamine enters the body fundamentally alters the experience:

• ●Intravenous (IV): Nearly 100% bioavailability. Onset within 30 to 60 seconds. The experience arrives abruptly, with little transition. Peak effects last 5 to 20 minutes, resolving within 60 to 120 minutes.
• ●Intramuscular (IM): Bioavailability around 90 to 95%. Onset in 3 to 5 minutes, allowing a more gradual entry with a similar intensity but a gentler arc.
• ●Intranasal: Bioavailability of roughly 50 to 75%. Onset over 5 to 15 minutes, building rather than arriving. This is the route used in FDA-approved esketamine and the most common in informal settings.
• ●Oral: Bioavailability drops to 20 to 30% due to extensive first-pass liver metabolism. Onset is gradual (20 to 45 minutes), the experience tends to feel softer, and the active metabolite norketamine plays a larger role. Duration extends to 60 to 180 minutes.

Ketamine is fully synthetic and has no traditional or indigenous use context. Its informal use emerged in the 1970s among medical professionals, expanding into club and electronic music culture through the 1990s and 2000s.

Ketamine was born from a problem. In the late 1950s, phencyclidine (PCP) had shown promise as a dissociative anesthetic, but its severe psychiatric side effects, including prolonged psychotic episodes and post-operative delirium, made it unsuitable for clinical use. The search for a safer alternative led to Parke-Davis Laboratories in Detroit, where chemist Calvin Lee Stevens synthesized compound CI-581 in 1962.

The first human administration came in 1965, when pharmacologist Edward F. Domino at the University of Michigan gave CI-581 to volunteers and documented something unusual: pronounced dissociative effects, preserved consciousness, rapid onset and offset, and, critically, intact airway reflexes. The compound could render someone insensible to pain while keeping them breathing on their own. Domino published his findings in Anesthesiology that same year, and by 1970, ketamine had received FDA approval for human anesthesia.

Adoption was rapid. Operating rooms across the country incorporated it into standard practice, and during the Vietnam War, ketamine became a staple of field medicine, valued for its speed, simplicity, and respiratory safety in conditions where maintaining an airway was essential.

Then the compound began to move beyond its intended setting. Through the 1970s and 1980s, anesthesiologists and medical professionals with pharmaceutical access began exploring ketamine recreationally. By the 1990s, it had entered club and electronic dance music culture, becoming associated with urban underground scenes, LGBTQ+ communities, and the broader rave movement. The DEA responded: Louisiana became the first state to schedule ketamine in 1998, and federal scheduling as a Schedule III substance followed in November 1999.

The story might have ended there, as another compound moving from medicine to recreation to prohibition. But in 2006, psychiatrist Carlos Zarate Jr. at the National Institute of Mental Health published a small, landmark study showing that a single intravenous infusion of ketamine could lift treatment-resistant depression within 24 hours, something no existing antidepressant could do. The finding challenged decades of assumption that antidepressants required weeks to work.

By 2019, the FDA had approved esketamine (the S-enantiomer of ketamine, marketed as Spravato) for treatment-resistant depression, granting the compound a clinical legitimacy it had not held since its anesthesia days. Today, ketamine occupies a position unlike any other compound in pharmacology: simultaneously an established surgical tool, a scheduled recreational substance, a rapid-acting psychiatric intervention, and the subject of intensive neuroscience research. Its arc from laboratory to operating room to dance floor to psychiatric clinic is, in many ways, the story of how society decides what a drug is for.

Ketamine's safety profile is well-studied in medical settings and less well-understood outside them. What follows is an honest accounting of what the evidence shows.

Psychological risks

Dissociative panic affects an estimated 5 to 15% of people who use ketamine. The sensation of losing contact with one's body and environment can produce intense fear, particularly for those who are unprepared or have a history of anxiety disorders. These episodes typically resolve within 30 to 60 minutes as the compound clears. In a smaller subset, deep dissociation can trigger depersonalization that persists for days to weeks, particularly in people with pre-existing vulnerability to dissociative states.

Physical risks

Ketamine raises heart rate and blood pressure, making it a concern for people with uncontrolled hypertension, coronary artery disease, or cardiac arrhythmias. Respiratory depression is rare at sub-anesthetic levels but becomes significant when combined with other depressants such as opioids, benzodiazepines, or alcohol. The most common acute physical risk in informal settings is accidental injury: impaired coordination and reduced pain perception leave people vulnerable to falls and environmental hazards.

Chronic use concerns

The most distinctive long-term risk is urological. Chronic high-frequency use (daily or near-daily over months to years) is associated with ketamine-associated lower urinary tract dysfunction (KALTD), presenting as painful urination, urgency, and reduced bladder capacity. Prevalence in chronic heavy users ranges from 2 to 9%. The risk appears strongly dose- and duration-dependent, and rare at clinical frequencies.

Psychological dependence develops in an estimated 10 to 15% of regular recreational users, often linked to using dissociation as an escape from emotional distress. Physical dependence is less pronounced than with opioids or benzodiazepines. Tolerance develops rapidly and reverses with brief abstinence.

Contraindications

Ketamine is contraindicated in people with untreated severe hypertension, recent myocardial infarction, unstable angina, or undiagnosed porphyria. Careful consideration is needed for those with active psychosis, severe liver or kidney disease, raised intracranial pressure, or active substance use disorders. Combining ketamine with other central nervous system depressants substantially increases respiratory risk.

Set, setting, and support

A safe physical environment, the presence of a trusted and sober person, and adequate preparation all reduce the likelihood of adverse outcomes. The absence of these factors does not guarantee harm, but their presence meaningfully reduces it.

The ketamine experience does not always leave clear footprints. Unlike serotonergic psychedelics, which often produce vivid, emotionally charged memories, ketamine's dissociative nature means that what happened during the session may return as fragments, impressions, or the vague residue of something significant that resists being put into words. Integration here is less about unpacking a narrative and more about learning to sit with what remains.

The hours immediately following a session are a transition. Dissociation fades gradually. Coordination returns, cognitive clarity rebuilds, and the familiar sense of self re-establishes itself, usually within two to six hours. During this window, many people report a subtle mood shift: a gentle elevation, a quiet calm, or, less commonly, a flat emptiness. None of these responses is wrong.

For those who experienced deep dissociation, the primary integration challenge is often not emotional overwhelm but something closer to perplexity: a sense that something happened that matters, without knowing exactly what it was.

What tends to help:

• ●Rest. The nervous system benefits from stillness after profound dissociation.
• ●Journaling. Writing down whatever fragments remain, even if they seem incoherent, can help the mind begin to organize the experience.
• ●Conversation. Speaking with someone who understands the territory, whether a therapist, a trusted friend, or a peer community, can reduce the isolation that sometimes follows unusual states of consciousness.
• ●Professional support. For those who notice persistent depersonalization, working with a therapist familiar with altered states can provide grounding.
• ●Time. Integration is not a single event but an ongoing practice. Meaning may arrive weeks later, or it may not arrive at all, and that is acceptable.

In clinical settings, integration support varies widely. Some ketamine-assisted psychotherapy programs include structured preparatory and follow-up sessions, while many infusion clinics focus primarily on the medical protocol with minimal psychological support. The emerging evidence suggests that outcomes tend to improve when the experience is embedded in a broader therapeutic context.

Not every session needs to produce insight. Sometimes the value is simply in the interruption, a brief departure from habitual patterns that allows something new to take root.

Ketamine carries no ecological footprint in the way that plant-based or fungal compounds do. It is fully synthetic, manufactured in pharmaceutical facilities, and its production does not threaten any species or ecosystem. There is no overharvesting concern, no endangered habitat, no indigenous tradition to honor or protect. In this sense, ketamine's ethical landscape is simpler than that of psilocybin, ayahuasca, or peyote.

But simplicity of sourcing does not mean absence of ethical complexity.

The most pressing ethical question surrounding ketamine today is access. FDA-approved esketamine (Spravato) costs $600 to $1,000 per session, with a full induction course running into thousands of dollars. Off-label ketamine infusions carry similar price tags. Insurance coverage is inconsistent and often requires extended patient advocacy. The result is a treatment landscape shaped primarily by wealth: clinical ketamine services concentrate in affluent urban areas, and the patient populations accessing them skew heavily toward white, higher-income demographics.

This creates a pointed contradiction. The communities most affected by the criminalization of ketamine possession have the least access to its clinical benefits. Recreational possession remains a felony in most jurisdictions, with enforcement patterns reflecting broader disparities in the criminal justice system.

The rapid commercialization of ketamine clinics raises additional questions. Many operate with minimal psychological support, administering infusions in a medical framework without the integration infrastructure that emerging evidence suggests improves outcomes. Private clinics are not required to publish their outcomes data, creating a transparency gap between marketed promises and documented results.

None of these concerns invalidate ketamine's genuine clinical value. They do, however, ask us to consider who benefits from a medicine, who is excluded from it, and what obligations accompany the act of making a powerful compound available on terms that not everyone can meet.